Aim: Application of mixed solvency concept has been employed in the present research work to develop the topical solution formulations of poorly water-soluble drug indomethacin (as a model drug). Material and Method: Due to the low solubility of indomethacin in water, combination of solubilizers as mixed solvent systems was used to decrease the overall concentration of solubilizers required to produce a substantial increase in solubility and thereby resulting in enhanced permeation of indomethacin from its topical formulation. The procured sample of indomethacin was characterized by melting point, infrared, ultraviolet, and differential scanning calorimeter studies. The formulations were evaluated for various properties of a solution such as pH, viscosity, freeze-thaw study, and thin layer chromatography. Stability studies of topical indomethacin solutions were performed for 2 months at room temperature, 30°C and 40°C. Result: The results of stability studies of indomethacin topical solution were satisfactory. It was found that 95.07%, 93.88% and 93.45% of drug was remaining after stability study at respective temperatures in batch first and 94.89%, 94.44% and 94.32% in batch second. Conclusion: Mixed solvency concept successfully employed to improve the drug loading of poorly water soluble drug indomethacin.
INTRODUCTION

D
rug delivery through topical route represents a most convenient and novel approach for the application to the skin for direct treatment of cutaneous disorder (e.g., acne) or the cutaneous manifestation of a general disease (e.g., psoriasis) having the intent of containing the pharmacological or different other effects of the drug for the surface of the skin and within the skin. The major difficulty comes while delivering a drug through the skin is its action as a natural barrier. The major barrier layer of the skin is the stratum. Molecules of the drug penetrate through the skin primarily through the tortuous and continuous intercellular paths. Only those drugs can penetrate which are in the form of the molecular state through the skin.
One of the oldest dosage forms which is used in the treatment of disease and has the rapid and very high absorption of soluble medicinal products is the solution. The solution which is applied directly to the skin is called topical solution. [1] Topical formulations are made in the vehicle, which can be optimized for a particular site of the body and various types of skin conditions. The product may be designed in such a way to maximize or to moisturize the penetration of an active ingredient and medicine, into or through the skin.
[2] Two major key characteristics that need to be taken into the consideration while compounding the solutions are solubility and stability.
[3] Topical solution acts locally and targets at the site of allergy and inflammation resulting in reduced side effects and toxicity to other organs. Low aqueous solubility is the main problem for the formulation development of the various other new chemical entities as well as for various generic developments. Water is the main solvent chosen for liquid pharmaceutical formulations. [4, 5] Solubility improvement techniques include derivatization, alteration of pH, cosolvency, hydrotropic solubilization, and mixed solvency.
As per the mixed solvency concept proposed by Maheshwari, each and every substance present in the universe has got solubilizing property, i.e., all the liquids, gases, and solids possess solubilizing power. As per his statement, each substance is solubilizer. A concentrated aqueous solution containing various water-soluble substances may act as good solvent for poorly water-soluble drugs. Such concentrated solutions may show synergistic or additive solubilizing actions of solubilizers present in the solution. Each and every weaker solvent (for a solute) can be made a strong solvent by proper selection of solubilizers. The concept of mixed solvency has been used to show the enhancement of aqueous solubility of a large number of poorly water-soluble drugs by employing the mixed solvency concept. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Application of mixed solvency has been employed in present research work to develop the topical solutions of indomethacin (used as a model poorly water-soluble drug). It is white to pale yellow crystalline powder, practically insoluble in water. It is soluble in ethanol, ether, acetone, and castor oil [ Figure 1 ]. Mixed-solvency can be employed as a tool to decrease the overall concentration of solubilizers required to produce a substantial increase in solubility and thereby resulting in enhanced permeation of indomethacin in its topical dosage form.
MATERIALS AND METHODS
Materials
Indomethacin was obtained as a gift sample from Elder Pharmaceutical Private Limited, Mumbai.
Estimation of Indomethacin
Ultraviolet (UV) spectrophotometric analysis of indomethacin
20 μg/ml solution of drug was scanned on a double-beam UV-visible spectrophotometer (Shimadzu® 1700) between wavelength ranges of 200 nm and 400 nm. UV spectrum was recorded in Figure 2 .
Infrared (IR) analysis of drug sample
The IR spectroscopy of indomethacin was performed for identification of drug. About 1-5 mg of the sample was triturated with approximately 300 mg of dry, finely powdered potassium bromide IR and compressed as pellet and spectra were recorded on Fourier transform IR (FTIR) spectrophotometer (Shimadzu 8400 S). The IR spectrum is presented in Figure 3 .
Differential scanning calorimeter (DSC) analysis of drug sample
To obtain the DSC thermograms of the drugs, a thermal analysis instrument, TA Instruments-2910 modulated DSC (USA) was employed. To carry out these studies, 1-4 mg of drug was weighed accurately and placed in one of the matched aluminum pans. The sample pan and the reference pan both were sealed and placed on the heating cell and covered with a glass bell jar. Heating at a rate of 10°C/min with a continuous purge of nitrogen (45 CC/min) was done with a recording of energy changes in the sample with respect to the reference in the temperature range of 80-200°C. The DSC thermogram is shown in Figure 4 .
Preparation of calibration curve of indomethacin in demineralized water
Fifty mg of drug indomethacin was accurately weighed and transferred to a 500 ml volumetric flask. To this, 10 ml of 30% w/v sodium benzoate solution was added to dissolve the drug, and the volume was made up to 500 ml with demineralized water to prepare a 100 μg/ml solution. Appropriate dilutions were made with demineralized water to obtain 5, 10, 15, 20, and 25, μg/ml solution of the drug. The absorbances of the resulting drug solutions were measured spectrophotometrically at 320 nm against the corresponding reagent blanks. The data were graphically represented in Figure 5 . 
Determination of Interference of Excipients in the Spectrophotometric Estimation of Indomethacin
Different excipients: Sodium benzoate, caffeine, niacinamide, and PEG 400 were used for the interference study. For determination of interference of excipients in the spectrophotometric estimation of indomethacin, the absorbances of the standard solutions of indomethacin were determined in DM water alone and the presence of the excipients. The absorbances were recorded against respective reagent blanks at 320 nm. Results are shown in Table 1 .
Drug Solubilizers Incompatibility Studies
The different formulation components involved in the development of proposed formulations were physically mixed with the drug in 1:1 ratio and filled in glass vials properly capped and sealed. The vials of each sample were kept at room temperature and in the refrigerator and thermostatically controlled oven maintained at 40°C for 1 month period. After every week for 1 month, the vials were withdrawn, and changes in physical appearance (if any) and color of the contents were observed.
Solubility Studies
Solubility of indomethacin in distilled water and aqueous solutions of various solubilizers were determined by equilibrium solubility method. The excess drug was added to 5 ml of distilled water, and mixed solvent systems [ Table 2 ] contained in 10 ml glass vials and vials were sealed with rubber closures and aluminum seals. The vials were shaken for 12 h in Orbital Flask Shaker (Khera Instruments Pvt. Ltd., Delhi, India) and allowed to equilibrate for 24 h undisturbed. The solutions containing an excess of the drug were centrifuged at 2200 r.p.m. for 5 min in ultracentrifuge and filtered through Whatman grade 5 filters. Aliquots of the filtrate were suitably diluted with distilled water, and the dilutions were analyzed on UV-visible spectrophotometer (Shimadzu 1700) against respective reagent blanks. Results are shown in Table 2 .
Formulation Development of Topical Solution
Based on the solubility studies, topical solutions were prepared using blends Q and T of mixed solvent systems. Sodium benzoate, niacinamide, and PEG 400 were taken in a 50 ml volumetric flask. Distilled water (25 ml) was added to the flask, and the flask was shaken to dissolve all the excipients. Then, caffeine was added, and flask was again shaken to solubilize it. Then, indomethacin was added, and the flask was shaken to solubilize the drug completely. Sufficient distilled water was then added to make up the volume up to 50 ml. After shaking the flask for complete homogenization, the solution was filtered through the filter paper, rejecting the first few ml of solution. The prepared solution was preserved in air-tight containers. The compositions of topical solutions are presented in Table 3 .
Stability Studies
Topical solutions of indomethacin of two different formulations were kept at different storage conditions. Formulations were kept at room temperature, at 30°C and 40°C. The results are shown graphically in Figures 6 and 7 .
EVALUATIONS OF TOPICAL INDOMETHACIN SOLUTIONS
Thin-Layer Chromatography (TLC) Analysis
TLC analysis was done to identify any drug-solubilizer interaction [ Table 4 ]. Methanol was used as a solvent for sample preparation for TLC of the drug.
pH of Topical Solutions of Indomethacin
Sample was taken in a dry 25 ml beaker and pH was recorded on a standardized pH meter fitted with glass calomel electrode.
Viscosity
The viscosities of the prepared topical solutions were measured by dial viscometer (Brookfield® LV). Required amount of the topical solutions was taken in 250 ml beakers individually. The dial readings were noted using all the spindles and at each spindle speed (one by one). The appropriate dial readings (10-90) were considered for calculations of viscosity in cps by multiplying the dial reading with the factor (specified according to the spindle number and the spindle speed). 
Freeze-Thaw Testing
Two vials of each topical solution were subjected to freezethaw stress testing to observe any chance of precipitation. For 24 h, the vials were stored at 4°C in the refrigerator and then vials were kept at 40°C in the oven for 24 h. After this, again, vials were kept at 4°C in the refrigerator for 24 h. After 7-7 such alternate cycles at 4°C and 40°C, the vials were observed for any precipitation or turbidity.
RESULTS AND DISCUSSION
Drug Characterization
UV spectrophotometric analysis of indomethacin
The indomethacin drug sample exhibited a peak at 320 nm which was comparable to the value reported in the literature.
IR analysis of drug sample
The FTIR spectrum of drug sample had shown identical peaks as reported in a reference sample of indomethacin.
DSC analysis of drug sample
The DSC curve of the crystalline form of indomethacin showed a sharp endothermic peak at 161.8°C attributable to the melting point. 
Preformulation Studies
Preparation of calibration curve of indomethacin in demineralized water
The calibration curve of indomithacin in DM water was plotted and it followed beer's lambert law.
Drug solubilizers interference studies in the spectrophotometric estimation of Indomethacin
Observing the results of drug-solubilizers interference study, it was concluded that there was no interference in UV spectrophotometric analysis of indomethacin due to excipients.
Drug solubilizers incompatibility studies
Observing the results of drug solubilizers compatibility study, it was concluded that there was no physical incompatibility between drug and selected formulation solubilizers.
Formulation Development
Solubility studies
Maximum increase in solubility of indomethacin was observed in Blend Q (20% sodium benzoate, 10% niacinamide, 10% caffeine, and 10% PEG 400) and in Blend T (20% sodium benzoate, 10% niacinamide, 15% caffeine, and 10% PEG 400) so these were selected to be used in formulation of topical solutions of indomethacin.
The solubility of the drug in distilled water was found to be 0.105 g/100 ml.
Stability studies
Stability studies of topical indomethacin solutions were performed for 2 months at room temperature, 30°C and 40°C and percentage drug remaining for first formulation (Batch First) at room temperature was 95.07%, and at 30°C was 93.88%, and at 40°C was 93.45%. Percent drug remaining for second formulation (Batch Second) at room temperature was 94.89%, at 30°C was 94.44%, and at 40°C was 94.32%. The results of stability studies of indomethacin topical solutions gave reasonably good results.
Evaluations
TLC analysis
From TLC study, it is clear that there is no significant change in R f value indicating that there were no interactions between drug and solubilizers.
pH of topical solutions of indomethacin
Preferably the pH of topical solutions should be in the range of 5.0-5.5. pH of topical indomethacin solution batch first was 5.3 and pH of topical indomethacin solution batch second was 5.4.
Viscosity
The measured viscosities of prepared topical solutions of indomethacin were found to be 1080cps-1300cps for the first batch and 860 cps-1120 cps for the second batch.
Freeze-thaw testing
Freeze-thaw study declared that there was no precipitation and no turbidity (after 7-7 such cycles).
SUMMARY AND CONCLUSION
The main objective of the present study was to explore the mixed solvency concept in the preparation of the topical solution of poorly water-soluble drug indomethacin. The aim was to make water, a strong solvent for the poorly watersoluble drug, indomethacin for the preparation of the topical solution of drug using mixed solvency concept by the use of safe solubilizers niacinamide, sodium benzoate, PEG 4000, PEG 400, caffeine, and glycerin.
To minimize the probable toxic effects of individual solubilizers at high concentration (individually), different blends of solubilizers were tried. The blends of solubilizers of different strength were used for the solubility studies to get sufficiently high expected solubilities. The combinations of different agents were tried.
The procured sample of indomethacin was characterized by melting point, I-R spectroscopy, UV characterization, and DSC study. The melting point of the drug sample was found to be 158°C (reported 155-160°C). Preformulation studies were performed which included solubility studies, preparation of calibration curves in demineralized water. The solubility of indomethacin drug sample in demineralized water was found to be 0.105 g/100 ml.
Different solubilizers, sodium benzoates, caffeine, niacinamide, PEG 400, and glycerin and were used for the interference study. For determination of interference of excipients in the spectrophotometric estimation of indomethacin, the absorbances of the standard solutions of indomethacin were determined in demineralized water alone and the presence of the excipients. The absorbances were recorded against respective reagent blanks at 320 nm. There is no interference in UV spectrophotometric analysis of indomethacin due to the presence of excipients.
Solubility studies were performed on 20 blends, and maximum increase in solubility of indomethacin was observed in Blend Q (20% sodium benzoate + 10% niacinamide + 10% caffeine + 10% PEG 400) and in Blend T (20% sodium benzoate + 10% niacinamide + 15% caffeine + 10% PEG 400) so these were selected to be used in formulation of topical solution of indomethacin. In Blend Q and Blend T, 2% drug concentration was used to formulate the topical solutions of indomethacin.
Stability studies of topical indomethacin solutions were performed for 2 months at room temperature, 30°C and 40°C and percentage drug remaining for the first formulation at room temperature was 95.07%, at 30°C was 93.88%, and at 40°C was 93.45%. Percentage drug remaining for the second formulation at room temperature was 94.89%, at 30°C was 94.44% and at 40°C was 94.32%. The results of stability studies of indomethacin topical solutions were reasonably good. For the evaluation, different studies were performed such as TLC, freeze-thaw study, viscosity, and pH, and satisfactory results were found.
The concept of mixed solvency was successfully employed in formulating the topical solution of poorly soluble model drug, indomethacin. In this study, there was no involvement of organic solvent to prepare a topical solution. The present study illustrates the novel application of mixed solvency concept to improve the drug loading of the poorly watersoluble drug. Pharmaceutical companies may be benefited by this concept, not only to manufacture a topical solution but also to develop other pharmaceutical formulations.
